Yang Qian, Ding Peng, Liu Yu-Xiang, Zhang Kai-Chen, Gao Pei-Yang
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Immunol. 2025 Mar 11;16:1546571. doi: 10.3389/fimmu.2025.1546571. eCollection 2025.
The pathogenesis of autoimmune hemolytic anemia (AIHA) remains incompletely understood, typically associated with immune dysfunction and the production of autoantibodies. Zuberitamab, a novel anti-CD20 monoclonal antibody, represents an important therapeutic strategy for managing autoimmune diseases. Here, we present the first case of a patient diagnosed with AIHA who developed severe immunosuppression, lymphopenia, and B-cell depletion following zuberitamab treatment, ultimately resulting in severe pneumonia(PJP). This case highlights the complexities of B-cell-targeted immunotherapy and underscores the necessity of close monitoring of immune status in patients receiving zuberitamab or other targeted immunotherapies to mitigate the risk of severe immune-related adverse events.
自身免疫性溶血性贫血（AIHA）的发病机制仍未完全明确，通常与免疫功能障碍和自身抗体的产生有关。新型抗CD20单克隆抗体Zuberitamab是治疗自身免疫性疾病的一项重要治疗策略。在此，我们报告首例确诊为AIHA的患者，该患者在接受Zuberitamab治疗后出现严重免疫抑制、淋巴细胞减少和B细胞耗竭，最终导致严重肺炎（肺孢子菌肺炎）。该病例凸显了B细胞靶向免疫治疗的复杂性，并强调了在接受Zuberitamab或其他靶向免疫治疗的患者中密切监测免疫状态以降低严重免疫相关不良事件风险的必要性。
